



Box
SAC: GAV 1654
231/181
Patent
NJD
HS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Nigel Robert Arnold Beeley et al.

Serial No. 09/003,869

Filed: January 7, 1998

For: USE OF EXENDINS AND
AGONISTS THEREOF FOR THE
REDUCTION OF FOOD
INTAKE

) Group Art Unit 1654

) Examiner DAVENPORT, A.

) TECH CENTER 1600/2900

RECEIVED

AUG 06 1999

RESPONSE TO COMMUNICATION

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Responsive to the Communication mailed March 31, 1999, enclosed is a computer
readable form copy of the Sequence Listing, a paper copy of the Sequence Listing, a Statement

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the
United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope
addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Sarah B. Navarro

Name of Person Mailing Paper

July 30, 1999

Date of Deposit

Sarah B. Navarro

Signature of Person Mailing Paper

SD-113811.1

08/04/1999 CUDRACHA 00000108 09003869

01 FC:217

435.00 0P

Under 37 C.F.R. § 1.821(f), and a copy of the Notice to Comply With Sequence Requirements.

Please amend the specification by entering the enclosed Sequence Listing. The Sequence Listing was generated from the specification and Figure 10, and does not constitute new matter.

Pursuant to 37 CFR §1.136, applicant hereby petitions for a three-month extension of time to take action in response to the Office Action mailed March 31, 1999. This extension of time is effective to allow timely filing of a Response up to and including July 31, 1999.

Enclosed is a check in the amount of \$435.00 for payment of the fee for the three-month extension. If the enclosed fee is incorrect, please charge or credit our Deposit Account 12-2475 for the appropriate amount.

Respectfully submitted,

Dated: July 30, 1999

By 
Peter R. Munson
Registration No. 43,821

LYON & LYON, LLP
First Interstate World Center
633 West Fifth Street, Suite 4700
Los Angeles, CA 90071-2066
(619) 552-8400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Nigel Robert Arnold Beeley et al

Serial No. 09/003,869

Filed: January 7, 1998

For: USE OF EXENDINS AND
AGONISTS THEREOF FOR THE
REDUCTION OF FOOD INTAKE

Group Art Unit: 1654

Examiner: DAVENPORT, A.



#5
Plunkett
9/15/99

STATEMENT UNDER 37 C.F.R. § 1.821 (F)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (e), (f) and (g), or § 1.825 (d) and (b) respectively, are the same. No new matter has been added. Please enter the Sequence Listing into the specification. Please note that Seq. ID Nos. 10-39 are shown in Figure 10.

Respectfully submitted,

LYON & LYON



Peter R. Munson
Registration No. 43,821

633 West Fifth Street
Suite 4700
Los Angeles, California 90071
(619) 552-8400

SD-113803.1


CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Sarah B. Navarro

Name of Person Mailing Paper

July 30, 1999
Date of Deposit



Signature of Person Mailing Paper



Application No.: 09/00 3865

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: _____

RECEIVED

AUG 06 1999

TECH CENTER 1600/2900

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE